Interaction of insulin, glucagon-like peptide 1, gastric inhibitory polypeptide, and appetite in response to intraduodenal carbohydrate

What Was Tested

This randomized controlled trial paper looks at Glucagon and GIP (Gastric Inhibitory Polypeptide).

The relation between gastrointestinal incretin hormones in the control of insulin release and short-term satiety by intestinal carbohydrate was investigated in 8 fasted, healthy male volunteers.

Studies were conducted under hyperinsulinemic and euglycemic conditions.

Who Took Part

The age groups tagged for this paper are adults, men only.

How the Study Was Run

In design terms this was a randomized and single-blind study.

Because people in this Glucagon study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Only one side, usually the participants, was kept unaware of whether Glucagon was given.

Insulin, gastric inhibitory polypeptide (GIP), glucagon-like peptide 1 (GLP-1), and appetite ratings were measured during, and food intake was measured after, intraduodenal infusions of glucose or saline.

What Was Measured

The relation between gastrointestinal incretin hormones in the control of insulin release and short-term satiety by intestinal carbohydrate was investigated in 8 fasted, healthy male volunteers.

PubMed files the paper under topics including Appetite, Blood Glucose, Diet, Energy Intake, Gastric Inhibitory Polypeptide, Gastrointestinal Agents and Glucagon.

What This Means in Plain Language

The paper is a randomized and single-blind study of Glucagon and GIP (Gastric Inhibitory Polypeptide).

The publication is from 1998 (The American journal of clinical nutrition), a journal based in United States.

More context: the Glucagon compound page and the GIP (Gastric Inhibitory Polypeptide) compound page, all human trials.